<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.thecerbatgem.com/2019/11/21/cyclacel-pharmaceuticals-nasdaqcycc-trading-up-14.html"/>
    <meta property="og:site_name" content="The Cerbat Gem"/>
    <meta property="article:published_time" content="2019-11-21T20:58:43+00:00"/>
    <meta property="og:title" content="Cyclacel Pharmaceuticals (NASDAQ:CYCC) Trading Up 14%"/>
    <meta property="og:description" content="Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) shares were up 14% during trading on Thursday . The stock traded as high as $0.49 and last traded at $0.49, approximately 214,200 shares changed hands during trading. A decline of 48% from the average daily volume of 409,247 shares. The stock had previously closed at $0.43. Several analysts have commented […]"/>
  </head>
  <body>
    <article>
      <h1>Cyclacel Pharmaceuticals (NASDAQ:CYCC) Trading Up 14%</h1>
      <address><time datetime="2019-11-21T20:58:43+00:00">21 Nov 2019, 20:58</time> by <a rel="author" href="https://www.thecerbatgem.com/author/teresa" target="_blank">Teresa Graham</a></address>
      <figure>
        <img src="https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&amp;zc=1&amp;src=https://www.marketbeat.com/logos/cyclacel-logo.jpg"/>
      </figure>
      <p>Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) shares were up 14% during trading on Thursday . The stock traded as high as $0.49 and last traded at $0.49, approximately 214,200 shares changed hands during trading. A decline of 48% from the average daily volume of 409,247 shares. The stock had previously closed at $0.43.</p>
      <p>Several analysts have commented on CYCC shares. <a href="https://www.americanconsumernews.net/scripts/click.aspx?Zacks=1">Zacks Investment Research</a> raised Cyclacel Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $0.50 price objective for the company in a research note on Monday. <a href="https://www.americanconsumernews.net/scripts/click.aspx?ValuEngine=1&amp;Symbol=CYCC">ValuEngine</a> downgraded Cyclacel Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday.</p>
      <p>The company has a 50 day simple moving average of $0.38 and a 200 day simple moving average of $0.50. The company has a current ratio of 7.65, a quick ratio of 7.65 and a debt-to-equity ratio of 0.08. The stock has a market capitalization of $6.71 million, a PE ratio of -0.79 and a beta of 3.00.</p>
      <p>A hedge fund recently raised its stake in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC raised its stake in shares of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 82.5% in the 2nd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund owned 1,102,400 shares of the biotechnology company’s stock after acquiring an additional 498,200 shares during the period. Renaissance Technologies LLC owned approximately 6.41% of Cyclacel Pharmaceuticals worth $596,000 as of its most recent SEC filing. 8.84% of the stock is owned by institutional investors and hedge funds.</p>
      <p><b>About Cyclacel Pharmaceuticals</b> (<a href="https://www.marketbeat.com/stocks/NASDAQ/CYCC/">NASDAQ:CYCC</a>)</p>
      <p>Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.</p>
      <p>See Also: <a href="https://www.marketbeat.com/financial-terms/how-do-mutual-funds-work/">How Do Mutual Funds Work?</a></p>
    </article>
  </body>
</html>